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(including BPO)-induced induction of ornithine decarboxylase activity and mRNA expression in mouse epidermis (24) . More recently, we also showed that silymarin exerts an exceptionally In both experimental animals and possibly in humans, cancers high protective effect against UVB radiation-, 12-O-tetradeof the skin, lung, colon, breast, prostate, cervix, bladder and canoylphorbol 13-acetate (TPA)-and okadaic acid-induced esophagus arise in epithelial tissues and acquire the ability to tumor promotion in mouse skin and that the anti-tumor grow and invade through the basement membrane (1). A promoting effects of silymarin are primarily targeted at stage I tumor promotion (25) (26) (27) preventive effect of silymarin against BPO-induced (i) tumor promotion, (ii) oxidative stress and (iii) inflammatory responses in mouse skin. Six-week-old female SENCAR mice were purchased from Harlan Sprague-Dawley (Indianapolis, IN) and maintained in our animal facility under standard conditions. The dorsal skin of the mice was shaved using electric clippers and mice in the resting phase of the hair cycle were used in all studies. For the tumor studies, the mice were randomly divided into three groups of 20 animals each. The mice in group I were left untreated and served as negative controls. Mice in groups II and III were topically applied on the dorsal shaved skin with a single 2.5 µg dose of DMBA in 0.2 ml of acetone/mouse as tumor initiator. One week later, animals in group II were treated topically with 0.2 ml of acetone and in group III with 6 mg of silymarin in 0.2 ml of acetone/mouse/application. Thirty minutes following these treatments, animals in both groups II and III were applied topically with 20 mg of BPO in 0.2 ml of acetone/mouse/application. The BPO alone (group II) or silymarin plus BPO treatments (group III) were repeated twice per week up to termination of the experiment at 40 weeks from the start of DMBA. We did not include a DMBA ϩ silymarin group in this study as we have previously shown that a 12 mg topical application of silymarin twice a week to DMBA-initiated SENCAR mouse skin does not have a tumor promoting effect (27) . The selection of 6 mg of silymarin in the present study was based on a recent study by us showing that this dose causes exceptionally high anti-tumor promoting at the termination of the experiment, the tumor volume on For the clarity of presentation of data, the tumor incidence and multiplicity results are shown only for alternate weeks of study.
the back of each mouse was also computed. The statistical significance of differences between tumor incidence in the silymarin-treated and untreated groups was determined by twotetrazolium by superoxide anions produced by potassium superoxide dissolved in dimethylsulfoxide (29) . One unit of tailed Fisher's exact test (25, 27) . For tumor multiplicity and tumor volume/tumor, two sample Wilcoxon rank sum and enzyme activity is defined as the amount of enzyme causing 50% inhibition of the reduction to formazan observed in the Student's t-tests, respectively, were used (25, 27) .
For antioxidant enzymes and other studies, all treatments blank. Catalase activity was determined by measuring the sample-catalyzed disappearance of H 2 O 2 at 240 nm (30) , and were done on a 4 cm 2 shaved area. The animals were divided into six groups with four mice in each group and were treated expressed as U/mg protein (1 U ϭ OD of 1 mM H 2 O 2 ). Glutathione peroxidase (GPX) activity was measured as disaptopically on the shaved area with 0.2 ml of acetone (group I) and 0 (group II), 3 (group III), 6 (group IV) or 9 mg (group pearance of NADPH at 340 nm (31) , and expressed as nmol NADPH oxidized/min/mg protein. The lipid peroxidation assay V) of silymarin/mouse each in 0.2 ml of acetone followed 30 min later by 20 mg of BPO in 0.2 ml of acetone except was done as detailed recently (27) . Myeloperoxidase (MPO) activity was determined by the method of Bradley et al. (32) for group I. In group VI, the mice were treated topically with 6 mg of silymarin alone in 0.2 ml of acetone. These treatments as detailed earlier (33) . Epidermal interleukin 1α (IL-1α) protein levels were determined as detailed recently (34) using were performed once. To assess the extent of BPO-induced edema in SENCAR mouse skin and the inhibitory effect of an ELISA kit (Endogen, Woburn, MA). For statistical analysis of the data, Student's t-test was used between the BPO and pre-application of different doses of silymarin, 24 h after BPO treatment a dial caliper was used to measure the skin bi-fold silymarin ϩ BPO groups.
In the studies assessing the preventive effect of silymarin thickness. Edema formation was expressed as net increase in skin bi-fold thickness between BPO-and non-BPO-treated on BPO-induced skin tumor promotion, as shown by the data in Figure 1 , topical application of silymarin prior to BPO groups. Immediately after this measurement, mice were killed and the dorsal treated skin was removed and used for further resulted in an exceptionally high preventive effect against BPO-induced tumor promotion in SENCAR mouse skin. No studies. The epidermis was separated from the whole skin and epidermal 100 000 g supernatant and microsomal fractions significant change was observed in the body weight gain profile between silymarin-and non-silymarin-treated groups prepared as described earlier (28) . Superoxide dismutase (SOD) activity was measured by inhibition of reduction of nitroblue of mice throughout the experiment (data not shown), which further supported the previous observation that silymarin applied topically has no apparent toxicity (25) (26) (27) . In terms of tumor incidence, an exceptionally high preventive effect of silymarin against tumor promotion was evident throughout the experiment ( Figure 1A ). When these data were analyzed at the termination of the experiment at 40 weeks, compared with the non-silymarin-treated positive controls showing 50% of mice with skin tumors, pre-application of silymarin resulted in only 15% of mice with tumors, giving 70% protection (P Ͻ 0.001) against tumor incidence ( Figure 1A ). When the preventive effects of silymarin were analyzed for delay in latency period of the onset of first tumor, compared with the positive control group, a 5 week delay in the latency period of the onset of first tumor was observed in animals treated with silymarin prior to BPO ( Figure 1A ). Similar to the tumor incidence data, pre-application of silymarin also showed a highly significant protection against tumor multiplicity throughout the experimental protocol ( Figure 1B Several studies have shown that topical application of skin tumor promoters induces a strong oxidative stress in mouse epidermis, which includes elevated levels of superoxide anions followed by H 2 O 2 and hydroxyl radicals and depletion of ical and molecular alterations, including tumor promotion, as observed with TPA (5-10,35,36), and that treatment of mouse skin with antioxidants protects against these oxidative condi-(P Ͻ 0.001) protection against BPO-induced depletion of SOD activity in mouse epidermis, respectively (Figure 2A ). tions and tumor promotion in skin (12) (13) (14) . As silymarin is also a very strong antioxidant capable of scavenging both free Similarly, BPO-induced depletion of epidermal catalase activity also recovered by 32 (P Ͻ 0.001), 57 (P Ͻ 0.001) and 72% radicals and ROS (16-20) and shows strong protection against BPO-induced tumor promotion, we also assessed its effect on (P Ͻ 0.001) following pre-treatment with 3, 6 and 9 mg of silymarin, respectively ( Figure 2B ). In the case of GPX activity, BPO-induced depletion of antioxidant enzyme activities in mouse epidermis. The results for antioxidant enzyme activities 3, 6 and 9 mg of silymarin showed 20 (P Ͻ 0.005), 57 (P Ͻ 0.001) and 67% (P Ͻ 0.001) protection, respectively of SOD, catalase and GPX in mouse epidermis from different groups are summarized in Figure 2 . Treatment of SENCAR ( Figure 2C ). In contrast to these inhibitory effects of silymarin on BPO-induced depletion of antioxidant enzyme activities, mice with BPO for 24 h resulted in a strong depletion of antioxidant enzyme activities in epidermis. The observed treatment of mouse skin with 6 mg of silymarin alone did not result in any change in the epidermal antioxidant enzyme reductions in enzyme activities for SOD, catalase and GPX in mouse epidermis following a single BPO application were 75, activities examined (Figure 2) . Under oxidative conditions, the superoxide anion is the first 87 and 61% of the acetone-treated negative control, respectively (Figure 2 ). In the studies assessing the effect of silymarin on ROS formed, which if not scavenged, ultimately leads to a highly reactive species, the hydroxyl radical, which attacks BPO-induced depletion of antioxidant enzyme activities, it showed a highly significant dose-dependent protection (Figure nucleic acid, protein and lipid-rich membranes causing severe cell damage leading to genetic alterations (37,38). In this 2). In the case of SOD, pre-application of silymarin at 3, 6 and 9 mg showed 18 (P Ͻ 0.005), 45 (P Ͻ 0.001) and 66% regard, the most studied markers of oxidative damage are lipid different groups were performed as described in Figure 2 . Twenty-four peroxidation in SENCAR mice. The treatments on the shaved dorsal area of hours after these treatments, a dial caliper was used to measure skin bi-fold mice in different groups were performed as described in Figure 2 . Twentythickness and edema formation was calculated as net increase in skin bi-fold four hours after these treatments, mice were killed, the treated area of the thickness. Each data bar represents the mean Ϯ SD of four mice; eight skin removed and epidermal microsomal fractions prepared. The epidermal measurements were made at different dorsal skin sites for each mouse. The lipid peroxidation activity was measured. Each data bar represents the mean down arrow indicates a percentage decrease in BPO-induced skin edema. Ϯ SD of four mice; each sample was assayed in triplicate. The down arrow indicates a percentage decrease in BPO-induced epidermal lipid peroxidation in mice.
peroxidation [malondialdehyde (MDA) formation] and DNA damage (8-hydroxydeoxyguanosine formation) (37, 38) . In recent studies we have shown that in vitro addition of silymarin to epidermal microsomal incubations inhibits lipid peroxidation in a concentration-dependent manner (26) . Based on this study and the data shown in Figure 2 , we also assessed the effect of pre-treatment with silymarin on BPO-induced lipid peroxidation in mouse epidermis. As shown by the data in Figure 3 , compared with the acetone-treated control, a single topical application of BPO resulted in strong induction of epidermal lipid peroxidation, as measured by MDA formation. However, pre-treatment of mouse skin with silymarin resulted in signific- different groups were performed as described in Figure 2 . Twenty-four A further increase in silymarin dose to 9 mg showed a hours after these treatments, mice were killed, the treated area of the skin comparable effect to that observed at 6 mg ( Figure 3 ). The removed, total MPO content extracted and MPO activity measured. Each data bar represents the mean Ϯ SD of four mice; each sample was assayed observed inhibitory effects of silymarin at 3, 6 and 9 mg were in triplicate. The down arrow indicates a percentage decrease in BPO-35 (P Ͻ 0.05), 80 (P Ͻ 0.001) and 87% (P Ͻ 0.001), induced skin MPO activity in mice. respectively (Figure 3 ). Silymarin alone, however, showed almost comparable epidermal lipid peroxidation to that in the acetone-treated negative control (Figure 3) . skin has been shown to result in neutrophil infiltration that is responsible, at least in part, for the oxidative conditions Based on the results showing that silymarin significantly inhibits BPO-induced tumor promotion and depletion of antioxfollowing TPA application to mouse skin (39-42). In a given tissue, MPO is utilized as a marker to quantify the total number idant enzyme activities, we also assessed the effect of silymarin on BPO-induced inflammatory responses in terms of skin of neutrophils present therein (32) . Based on the data showing that silymarin protects against BPO-induced depletion of edema, neutrophil infiltration (by measuring MPO activity) and an increase in inflammatory cytokine IL-1α in mouse antioxidant enzyme activities and BPO-induced skin edema, we next assessed its effect on BPO-induced neutrophil infiltraepidermis. As measured by a net increase in the skin bi-fold thickness, compared with the acetone-treated negative controls, tion by measuring MPO. As shown in Figure 5 , 24 h after application of a single dose of BPO to mouse skin, total MPO a single topical application of BPO to mouse skin resulted in a strong increase in skin bi-fold thickness (edema) in SENCAR activity increased from not detectable to 53 U/mg epidermal protein. This increase in the level of tissue MPO indicates an mice (Figure 4) . However, the application of different doses of silymarin prior to BPO treatment resulted in a highly influx of neutrophils into the inflamed skin. Pre-application of silymarin before BPO, however, resulted in a significant significant inhibition of BPO-induced skin edema (Figure 4) . The observed inhibitory effects of silymarin were dose dependprotection against BPO-induced infiltration of neutrophils in a dose-dependent manner ( Figure 5) . Compared with the BPOent and evident as 62, 77 and 85% inhibition (P Ͻ 0.001) at 3, 6 and 9 mg of silymarin, respectively (Figure 4) . Similar treated samples, 3 mg of silymarin showed 42% protection (P Ͻ 0.001) against BPO-induced total MPO content ( Figure 5) . to other studies, silymarin alone applied topically at 6 mg showed no skin edema (Figure 4) .
Much stronger effects of silymarin were observed at 6 and 9 mg, which showed 77% and complete inhibition (P Ͻ 0.001) Topical application of the tumor promoter TPA to mouse In this regard, the results of the present study showing that silymarin protects against BPO-induced tumor promotion may be of great significance in preventing any tumor promotion risk associated with BPO exposure. Taken together, based on our recent studies and the results of the present study, we suggest that silymarin could be a useful cancer preventive agent against a wide range of carcinogen and tumor promoterinduced epithelial cancers in humans. the clonal expansion of initiated cells in the first place (5,6).
